PACTR201704002215604招募中未知
An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- DNDi
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 100 Year(s)（—）
- 性别
- All
入选标准
- •* Male or female patient, including breastfeeding or pregnant women in the second or third trimester.
- •* ¿ 6 years of age.
- •* ¿ 20 kg body weight.
- •* Signed Informed Consent Form
- •* Trypanosomes detected in any body fluid.
- •* Physically able to ingest at least one solid meal per day.
- •* Able to take oral medication.
- •* Karnofsky Performance Status > 40%.
- •* Able to comply with the schedule of follow-up visits and with the study constraints.
- •* Easily reachable during the out-patient follow-up period.
- •* Willing to undergo lumbar punctures.
- •Eligibility Criteria for Out-patient Treatment:
- •- Accepting to be treated on an out-patient basis.
- •- Karnofsky Performance Status > 50%.
- •- Good understanding of the method of administration of fexinidazole by the patient and/or caregiver (checked using a questionnaire at the time of IMP dispensing).
- •- Residing close to the investigational centre, i.e. approximately one hour by road and/or boat, during the treatment period*.
- •- Easily reachable during the treatment period.
- •- No medical or psychiatric contraindications for treatment as out-patient.
- •- No pregnancy or breastfeeding.
- •- No neurological symptoms.
- •*The patient (and caregiver) is permitted to reside in a place different from his/her main place of residence during the treatment period.
排除标准
- •* Active clinically relevant medical conditions other than HAT that, in the Investigator¿s opinion, could jeopardise patient safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or altered consciousness not related to HAT.
- •* Severe renal or hepatic impairment defined as:
- •o elevated creatinine at > 3 times the upper limit of normal (ULN)
- •o elevated ALT, AST or bilirubin at > 3 ULN
- •* Severely deteriorated general condition, such as cardiovascular shock, respiratory distress or terminal illness.
- •* Any condition (except symptoms of HAT) that compromises ability to communicate with the Investigator as required for completion of the study.
- •* Any contraindication to imidazole products (known hypersensitivity to imidazoles).
- •* Treatment for HAT within 2 years prior to inclusion.
- •* Prior enrolment in the study or prior intake of fexinidazole.
- •* Foreseeable difficulty in complying with the schedule of follow-up visits (migrants, refugees, itinerant traders, etc.).
- •Temporary Non-inclusion Criteria:
- •* Recovery period after antimalarial treatment and/or treatment of helminthiasis (at least 3 days).
- •* Uncontrolled diabetes or hypertension or any patients requiring clinical stabilisation; wait until appropriate treatment to control the disease has been initiated.
- •* First trimester of pregnancy.
- •* Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for 48 hours before repeating lumbar puncture.
研究者
相似试验
进行中（未招募）
1 期
Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver TransplantHereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003519-24-DEAlnylam Pharmaceuticals, Inc.20
进行中（未招募）
1 期
Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver TransplantEUCTR2018-003519-24-ITALNYLAM PHARMACEUTICALS, INC.20
进行中（未招募）
1 期
Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver TransplantHereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003519-24-FRAlnylam Pharmaceuticals, Inc.20
进行中（未招募）
1 期
Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver TransplantHereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003519-24-PTAlnylam Pharmaceuticals, Inc.23
进行中（未招募）
1 期
Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver TransplantHereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003519-24-GBAlnylam Pharmaceuticals, Inc.20